This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2023 May;78(5):1369-1371.

doi: 10.1111/all.15620. Epub 2022 Dec 21.

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit

Anthony D Dorr¹, Charu Chopra², Tanya I Coulter³, John Dempster⁴, Magdalena Dziadzio⁴, Tariq El-Shanawany⁵, Tomaz Garcez⁶, Mark Gompels⁷, Richard Herriot⁸, Rashmi Jain⁹, Marcel Levi⁴, Lorena Lorenzo¹, Inas Makki³, Elizabeth Mapazire¹, Sai H K Murng¹⁰, Sadia Noorani¹¹, Sinisa Savic¹², Cathal L Steele¹³, Christine Symons¹⁴, Michael Tarzi¹⁵, Patrick F K Yong¹⁶, Sorena Kiani-Alikhan¹

Affiliations

Affiliations

¹ Barts Health NHS Trust, London, UK.
² Royal Infirmary of Edinburgh, Edinburgh, UK.
³ Belfast Health and Social Care Trust, Belfast, UK.
⁴ University College London Hospitals NHS Foundation Trust, London, UK.
⁵ University Hospital of Wales, Cardiff, UK.
⁶ Manchester University NHS Foundation Trust, Manchester, UK.
⁷ North Bristol NHS Trust, Bristol, UK.
⁸ NHS Grampian, Aberdeen, UK.
⁹ Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
¹⁰ Epsom and St Helier University Hospitals NHS Trust, Carshalton, UK.
¹¹ Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
¹² St James's University Hospital, Leeds, UK.
¹³ NHS Tayside, Dundee, UK.
¹⁴ Plymouth Hospitals NHS Trust, Plymouth, UK.
¹⁵ Brighton and Sussex University Hospital NHS Trust, Brighton, UK.
¹⁶ Frimley Health NHS Foundation Trust, Frimley, UK.

PMID: 36510404
DOI: 10.1111/all.15620

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit

Anthony D Dorr et al. Allergy. 2023 May.

. 2023 May;78(5):1369-1371.

doi: 10.1111/all.15620. Epub 2022 Dec 21.

Authors

Anthony D Dorr¹, Charu Chopra², Tanya I Coulter³, John Dempster⁴, Magdalena Dziadzio⁴, Tariq El-Shanawany⁵, Tomaz Garcez⁶, Mark Gompels⁷, Richard Herriot⁸, Rashmi Jain⁹, Marcel Levi⁴, Lorena Lorenzo¹, Inas Makki³, Elizabeth Mapazire¹, Sai H K Murng¹⁰, Sadia Noorani¹¹, Sinisa Savic¹², Cathal L Steele¹³, Christine Symons¹⁴, Michael Tarzi¹⁵, Patrick F K Yong¹⁶, Sorena Kiani-Alikhan¹

Affiliations

¹ Barts Health NHS Trust, London, UK.
² Royal Infirmary of Edinburgh, Edinburgh, UK.
³ Belfast Health and Social Care Trust, Belfast, UK.
⁴ University College London Hospitals NHS Foundation Trust, London, UK.
⁵ University Hospital of Wales, Cardiff, UK.
⁶ Manchester University NHS Foundation Trust, Manchester, UK.
⁷ North Bristol NHS Trust, Bristol, UK.
⁸ NHS Grampian, Aberdeen, UK.
⁹ Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
¹⁰ Epsom and St Helier University Hospitals NHS Trust, Carshalton, UK.
¹¹ Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
¹² St James's University Hospital, Leeds, UK.
¹³ NHS Tayside, Dundee, UK.
¹⁴ Plymouth Hospitals NHS Trust, Plymouth, UK.
¹⁵ Brighton and Sussex University Hospital NHS Trust, Brighton, UK.
¹⁶ Frimley Health NHS Foundation Trust, Frimley, UK.

PMID: 36510404
DOI: 10.1111/all.15620

No abstract available

PubMed Disclaimer

References

REFERENCES

1. Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
1. Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77(3):979-990.
1. The National Institute for Health and Care Excellence. Lanadelumab for preventing recurrent attacks of hereditary angioedema Technology appraisal guidance [TA606] 2019. Accessed March 29, 2022. https://www.nice.org.uk/guidance/ta606
1. HSCNI. Northern Ireland Formulary. 2019. Accessed March 29, 2022. https://niformulary.hscni.net/managed-entry/managed-entry-decisions/
1. Scottish Medicines Consortium SMC2206 2019. Accessed March 29, 2022. https://www.scottishmedicines.org.uk/media/4947/lanadelumab-takhzyro-fin...

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley